• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

作者信息

Bakker Daphne S, Ariens Lieneke F M, Giovannone Barbara, Hijnen DirkJan, Delemarre Eveline M, Knol Edward, Nierkens Stefan, de Bruin-Weller Marjolein S, Thijs Judith L, Drylewicz Julia

机构信息

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

Center for Translational Immunology, Utrecht, The Netherlands.

出版信息

Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.

DOI:10.1111/all.14492
PMID:33305359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7754122/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d178/7754122/759268b91616/ALL-75-3287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d178/7754122/46950635981f/ALL-75-3287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d178/7754122/759268b91616/ALL-75-3287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d178/7754122/46950635981f/ALL-75-3287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d178/7754122/759268b91616/ALL-75-3287-g002.jpg

相似文献

1
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.湿疹面积和严重程度指数（EASI）与改良湿疹面积和严重程度指数（p-EASI）：使用血清生物标志物组合预测接受度普利尤单抗治疗的特应性皮炎患者的疾病严重程度
Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.
2
The beginning of biological treatment era in the atopic dermatitis management.特应性皮炎管理中生物治疗时代的开端。
Dermatol Ther. 2016 May;29(3):208-9. doi: 10.1111/dth.12277. Epub 2015 Aug 31.
3
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.
4
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.度普利尤单抗与环孢素治疗成人中重度特应性皮炎：基于湿疹面积及严重程度指数的间接比较
Acta Derm Venereol. 2019 Sep 1;99(10):851-857. doi: 10.2340/00015555-3219.
5
Dupilumab (Dupixent) for moderate to severe atopic dermatitis.度普利尤单抗（达必妥）用于治疗中度至重度特应性皮炎。
Med Lett Drugs Ther. 2017 Apr 24;59(1519):64-66.
6
Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.生物制剂治疗特应性皮炎有效吗？系统评价和荟萃分析。
Am J Clin Dermatol. 2018 Apr;19(2):145-165. doi: 10.1007/s40257-017-0324-7.
7
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
8
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.度普利尤单抗在一大群难治性成人特应性皮炎患者中非常有效：来自 BioDay 登记处的首个临床和生物标志物结果。
Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.
9
Dupilumab for treatment of atopic dermatitis.度普利尤单抗治疗特应性皮炎。
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.
10
Severe Adult Atopic Dermatitis: Clinical Challenges.重度成人特应性皮炎：临床挑战
Dermatitis. 2020 Jul/Aug;31(4):e48-e49. doi: 10.1097/DER.0000000000000592.

引用本文的文献

1
Evaluation of the levels of interleukins IL-4, IL-13, IL-5, IL-10 and IL-33 in atopic dermatitis patients with and without dupilumab therapy.评估接受和未接受度普利尤单抗治疗的特应性皮炎患者体内白细胞介素IL-4、IL-13、IL-5、IL-10和IL-33的水平。
Front Immunol. 2025 Jul 23;16:1604883. doi: 10.3389/fimmu.2025.1604883. eCollection 2025.
2
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.曲罗芦单抗治疗成人特应性皮炎患者：临床疗效、安全性、血清蛋白和总IgE水平的28周评估
Allergy. 2025 Apr;80(4):1060-1073. doi: 10.1111/all.16414. Epub 2024 Dec 14.
3

本文引用的文献

1
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.度普利尤单抗在一大群难治性成人特应性皮炎患者中非常有效：来自 BioDay 登记处的首个临床和生物标志物结果。
Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.
2
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A.湿疹面积及严重程度指数（EASI）与改良湿疹面积及严重程度指数（p-EASI）：预测接受环孢素A治疗的特应性皮炎患者的疾病严重程度
Allergy. 2019 Mar;74(3):613-617. doi: 10.1111/all.13651. Epub 2018 Dec 16.
3
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis.
探索白细胞介素-4和白细胞介素-13血浆水平作为特应性皮炎生物标志物的潜力。
Life (Basel). 2024 Mar 7;14(3):352. doi: 10.3390/life14030352.
4
Prediction of disease severity using serum biomarkers in patients with mild-moderate Atopic Dermatitis: A pilot study.使用血清生物标志物预测轻度至中度特应性皮炎患者的疾病严重程度：一项初步研究。
PLoS One. 2023 Nov 2;18(11):e0293332. doi: 10.1371/journal.pone.0293332. eCollection 2023.
5
[Molecular diagnosis of hand eczema].[手部湿疹的分子诊断]
Dermatologie (Heidelb). 2023 Jun;74(6):410-415. doi: 10.1007/s00105-023-05148-z. Epub 2023 Jun 5.
6
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.度普利尤单抗在特应性皮炎患儿中的临床应用：BioDay 注册研究 28 周的临床和生物标志物结果。
Pediatr Allergy Immunol. 2022 Dec;33(12):e13887. doi: 10.1111/pai.13887.
7
Advances and highlights in biomarkers of allergic diseases.过敏性疾病生物标志物的研究进展与亮点。
Allergy. 2021 Dec;76(12):3659-3686. doi: 10.1111/all.15089. Epub 2021 Sep 27.
8
Does Monthly Dupilumab Therapy Maintain its Clinical Efficacy in Moderate-to-Severe Atopic Dermatitis?每月一次的度普利尤单抗治疗对中重度特应性皮炎是否能维持其临床疗效？
Allergy Asthma Immunol Res. 2021 Sep;13(5):681-683. doi: 10.4168/aair.2021.13.5.681.
9
Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.血清胃蛋白酶原和糖类抗原72-4（CA72-4）联合胃泌素-17（G-17）检测在早期胃癌筛查、诊断及评估中的应用
J Gastrointest Oncol. 2021 Jun;12(3):1042-1048. doi: 10.21037/jgo-21-254.
10
Biomarkers in Hereditary Angioedema.遗传性血管性水肿的生物标志物。
Clin Rev Allergy Immunol. 2021 Jun;60(3):404-415. doi: 10.1007/s12016-021-08845-6. Epub 2021 Feb 9.
度普利尤单抗可改善特应性皮炎患者的全身性和皮肤异常。
J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5.
4
Therapeutic pipeline for atopic dermatitis: End of the drought?特应性皮炎的治疗领域：干旱的尽头？
J Allergy Clin Immunol. 2017 Sep;140(3):633-643. doi: 10.1016/j.jaci.2017.07.006.
5
EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients.湿疹面积及严重程度指数（EASI）与改良湿疹面积及严重程度指数（p-EASI）：联合使用多种血清生物标志物可为特应性皮炎患者的疾病严重程度提供一种客观的测量工具。
J Allergy Clin Immunol. 2017 Dec;140(6):1703-1705. doi: 10.1016/j.jaci.2017.06.046. Epub 2017 Aug 16.
6
Biomarkers for atopic dermatitis: a systematic review and meta-analysis.特应性皮炎的生物标志物：一项系统评价和荟萃分析。
Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453-60. doi: 10.1097/ACI.0000000000000198.
7
Atopic dermatitis diagnostic criteria and outcome measures for clinical trials: still a mess.特应性皮炎临床试验的诊断标准和结局评估：仍然一团糟。
J Invest Dermatol. 2011 Mar;131(3):557-9. doi: 10.1038/jid.2010.369.
8
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways.辅助性T细胞17细胞因子白细胞介素（IL）-17和IL-22调节不同的炎症和角质形成细胞反应途径。
Br J Dermatol. 2008 Nov;159(5):1092-102. doi: 10.1111/j.1365-2133.2008.08769.x. Epub 2008 Aug 5.
9
Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity.特应性皮炎：外周血T细胞活化、嗜酸性粒细胞增多及血清因子与临床严重程度的相关性
Clin Exp Allergy. 1993 Feb;23(2):145-53. doi: 10.1111/j.1365-2222.1993.tb00310.x.
10
Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis.特应性皮炎患者血清可溶性白细胞介素-2受体（sIL-2R）和嗜酸性粒细胞阳离子蛋白（ECP）水平
J Dermatol Sci. 1994 Apr;7(2):89-95. doi: 10.1016/0923-1811(94)90081-7.